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Abstract 
The investigation of bone is an interesting field in research involving crosstalk between several cells 
of different origins including several pathways of which many are still to be discovered and 
characterised. Through this system, a constant remodelling of the skeleton throughout the lifespan 
of a human is administered. If this system is no longer in homeostasis, it can lead to osteoporosis – 
a very invasive disease of which many elderly people suffers, in particular post-menopausal 
women. Involvement of the purinergic P2X7 receptor in regulation of bone formation has been 
reported. In addition, a subsequent identification of several single nucleotide polymorphisms 
(SNPs) within its gene has also been documented. This project has its basis in indicative findings of 
the negative and positive effect from SNPs in the P2X7 receptor gene has on the development of 
osteoporosis.  
As a result, it is the aim of this report to investigate the cellular effect of three selected SNPs 
transfected into an osteoblastic cell line in order to determine functional changes in the receptor 
followed by an analysis of the pattern of expression in selected bone markers. This was approached 
by inducing a single point mutation using site directed mutagenesis in the P2X7 receptor gene 
whilst it sits in a plasmid. This is followed by transfection of the plasmid into ROS 17/2.8 cells 
using Lipofectamine 2000 and a subsequent examination of change in receptor function by looking 
at changes in intracellular calcium concentration using. In addition, seven bone markers are tested 
for change in gene expression by RT-qPCR.  
A functional change of the P2X7 receptor observed by a change in intracellular calcium 
concentration was found for two SNPs according to their gain- or loss-of-function character when 
compared to WT. In contrast, the third SNP induced no significant change in function of the P2X7 
receptor when compared to WT.  
For the seven bone markers, although significant differences between SNPs and WT was observed, 
no tangible patterns of increase or decrease in boneformation seen as a result of change in bone 
markers was observed.    
 
4 
 
Abstrakt 
Undersøgelsen af knogle er et interessant område i forskning, som involverer interaktion mellem 
flere celler af forskellig oprindelse, herunder flere reaktionsveje, hvoraf mange stadig mangler at 
blive opdaget og karakteriseret. Gennem dette system, administreres en konstant ombygning af 
skelettet under hele livstiden for et menneske. Hvis dette system ikke længere er i homeostase, kan 
det føre til knogleskørhed - en meget invasiv sygdom , som mange ældre mennesker lider af, især 
postmenopausale kvinder. Involvering af den purinergiske P2X7 receptor i reguleringen af 
knogledannelse er blevet rapporteret. Derudover er en efterfølgende identifikation af flere enkelt 
nucleotid polymorphismer (SNPer) i dets gen også blevet dokumenteret. Dette projekt har sin basis 
i resultater der viser den negative og positive effekt som SNPer i P2X7 receptor genet har på 
udviklingen af osteoporose. 
Som følge heraf er det formålet med denne rapport at undersøge den cellulære virkning af tre 
udvalgte SNPer transficeret ind i en osteoblast cellelinie for at fastslå funktionelle ændringer i 
receptoren efterfulgt af en analyse af mønster i ekspressionen af udvalgte knoglemarkører. Dette 
blev gjort ved at inducere en enkel punkt mutation i P2X7 receptor genet, mens det sidder i et 
plasmid. Derefter bliver plasmidet transfekteret ind i ROS 17/2.8 celler vha. Lipofektamin 2000 og 
en efterfølgende undersøgelse af ændringer i receptor funktionen ved at se på ændringer i den 
intracellulære calciumkoncentration. Desuden er syv knoglemarkører testes for ændringer i 
genekspression ved brug af RT-qPCR . 
En funktionel ændring af P2X7 receptoren observeret ved en ændring i den intracellulære 
calciumkoncentration blev fundet for to SNPer i henhold til deres gain- eller loss-of-function 
karakter i forhold til WT. I modsætning hertil blev der ikke observeret nogen signifikant ændring i 
funktionen af P2X7 -receptoren i forhold til WT i den tredje SNP. 
For de syv knoglemarkører, selvom der blev observeret signifikante forskelle mellem SNPs og WT, 
var der ingen håndgribelige mønstre at spore i forhold til stigning eller fald i boneformation set som 
et resultat af ændringer i knoglemarkører.   
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Introduction 
For decades, bone has been regarded as being a solid structure onto which all other organs directly 
or indirectly could adhere. However, with the expansion of molecular biology the field in bone 
research has come into its stride. It has revealed a world of exciting cross talk between cells and an 
amazing ability of bones to adapt to changes in needs and environmental fluctuations. This is seen 
when astronauts come back from outer space with a lower bone mineral density (BMD) (S. M. 
Smith et al. 2014), or when athletes like tennis players develop stronger, fitter bones in the arm 
holding the racket (G. Ducher et al. 2005).  
The processes responsible for bone development in healthy individuals are also affected in the 
pathological field of bone disease. Diseases affecting bone such as osteoporosis has a great impact 
on the individual and in socioeconomically relations. It is therefore of great importance that this 
disease is addressed in order to help people, in particular elderly, to get a meaningful existence. 
In regard to osteoporosis, it has been shown through a cohort study of Danish postmenopausal 
women (N. R. Jorgensen et al. 2012) that several single nucleotide polymorphisms (SNPs) within 
the purinergic P2X7 receptor has a great impact in the risk of developing osteoporosis after entering 
menopause. It was found for several SNPs that they could have either a positive or a negative 
impact on the risk of developing osteoporosis, depending on whether the SNP was of gain- or loss-
of-function character, respectively. The same study is the foundation of this project, where plasmids 
with SNPs in the P2X7 receptor gene are inserted into osteoblasts and tested in different assays in 
relations to the wild type (WT) phenotype. Here three SNPs are presented and analysed - two gain-
of-function SNPs: His155Tyr (489C→T) (G. Cabrini et al. 2005;S. Roger et al. 2010), from now on 
referred to as 155, and Ala348Thr (1068G→A) (C. Sun et al. 2010), from now on referred to as 348, 
and one loss-of-function SNP: Arg307Gln (946G→A) (B. J. Gu et al. 2004), from now on referred 
to as 307.    
 
Bone structure  
The skeleton has vital jobs for the function of the body. It gives support for the body thus enabling 
man to stand upright and with attachment of muscles, it provides means of movement. It offers 
protection of the vital body parts such as the brain and thorax while also providing storage for 
minerals. Furthermore, the bone marrow is a storage for adipose tissue in some parts of the skeleton 
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while other parts is devoted to production of blood cells - both erythrocytes and leucocytes (Rod 
Seeley et al. 2011).    
The bone matrix consists of about 35% organic and 65% inorganic material (Rod Seeley et al. 
2011). The organic part is mostly proteoglycans and collagen with the latter giving flexibility to the 
bones material (Rod Seeley et al. 2011). The inorganic material is a highly substituted analogue of 
hydroxyapatite [Ca10(PO4)6(OH)2] (Adele L.Boskey, Pamela Gehron Robey 2013). The primary 
substitutions are carbonate, magnesium and acid phosphate which, in addition to other components 
in the molecular structure of hydroxylapatite, provide a source of calcium, phosphate and 
magnesium to the body when needed (Adele L.Boskey, Pamela Gehron Robey 2013). Furthermore, 
the mineral interact with collagen to strengthen its structure thus making the bones more resilient to 
mechanical load, though more subgroups of so-called noncollagenous proteins and proteoglycans 
help mediate the strength and structure of bone matrix (Adele L.Boskey, Pamela Gehron Robey 
2013).  
When bone is produced, an enzyme worthy of mentioning is the glycoprotein alkaline phosphatase 
(ALP). Though not functionally defined and subjected to a lot of discussion, the importance 
however, of this enzyme in regards to bone formation has been found through the study of alkaline 
phosphatase deficient mice (H. C. Anderson et al. 2004). Here a skeletal hypomineralization was 
shown thought to have occurred as a result of pyrophosphate (PPi) build-up which is to be expected 
when ALP can no longer catalyse the breakup of PPi to yield monophosphate (Pi) - vital when 
incorporating phosphate into bone matrix. Thus a proposed function of ALP is to hydrolyse PPi in 
order to increase local phosphate concentration while additionally be a potential calcium carrier 
(Adele L.Boskey, Pamela Gehron Robey 2013).  
 
Bone cells  
Osteoclasts 
Osteoclasts are terminally differentiated nonproliferating cells with a very short life span derived 
from the fusion of mononuclear precursor cells of the hematopoietic granulocyte-macrophage 
lineage (P. V. Giannoudis et al. 2007;S. Tanaka et al. 2003).  
Osteoclasts are accountable for the breakdown of bone. They form a so-called ruffled border at the 
site where their plasma membrane contacts the bone matrix. From the osteoclasts, hydrogen ions are 
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pumped across the plasma membrane to break down the matrix while enzymes are produced to 
digest the protein components (Rod Seeley et al. 2011).  
For good reasons, the osteoclasts are under tight control from a pathway called the 
OPG/RANKL/RANK system, using both inhibitory and promoting regulation (S. Khosla 2001). 
RANK (receptor activator of nuclear factor κB) is expressed on osteoclast precursors with RANKL 
(receptor activator of nuclear factor κB ligand) as its ligand leading to differentiation and activation 
of osteoclasts when activated and a net decrease in bone matrix. OPG (osteoprotegerin) works in an 
opposite fashion by being a decoy protein for RANKL leaving RANK unstimulated thus resulting 
in decreased differentiation and activation of osteoclasts (S. Khosla 2001).   
By producing RANKL in both membrane bound and free floating forms while also secreting OPG, 
the osteoblasts are orchestrating this system, thus having the ability to both inhibit and promote 
osteoclast activation and differentiation (S. Khosla 2001).  
 
Osteoblasts 
Osteoblasts are the bone forming cells, reviewed by (C. V. Gay et al. 2000). They reside on bone 
surfaces where bone is actively formed. Inactive bone surfaces also have osteoblasts, but in a 
quiescent state. Other cells called bone lining cells also reside at this site and are believed to be 
readily transformable into osteoblasts.    
Active osteoblasts are plump, cuboidal cells with a large endoplasmic reticulum (ER) – 
characteristic of cells synthesizing vast amounts of protein. Osteoblasts are asymmetric, having the 
capacity to produce bone on one side and respond to regulatory signals on the other (C. V. Gay et 
al. 2000). Furthermore, they secrete a calcifiable matrix mainly consisting of collagen, but also 
noncollagenous protein including osteopontin, osteonectin, bone sialoprotein and osteocalcin (C. V. 
Gay et al. 2000). 
Osteoblasts stems from mesenchymal stem cells (MSCs). These cells are pluripotens cells, capable 
of differentiating into chondrocytes, adipocytes, myocytes and of course osteoblasts (David J.J.de 
Gorter, Peter ten Dijke 2013). Differentiation toward the osteoblastic lineage depends on both Wnt 
and runt-related transcription factor2 (Runx2) with the latter being the primary mediator. This was 
shown by Otto et al who produced knockout mice lacking the Runx2 gene (F. Otto et al. 1997). 
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When born, the mice did not survive beyond 20 minutes caused by insufficient breathing and when 
analysed they had no osteoblasts and no ossification throughout their entire skeleton. Further 
indications showing the importance of Runx2 is its direct regulation of another important 
transcription factor called osterix encoded by the Sp7 gene. As in the case with Runx2, mice lacking 
osterix show no sign of ossification or indeed any osteoblasts, and die shortly after birth (K. 
Nakashima et al. 2002). However, regarding Runx2 the same study found that Runx2 was 
unaffected by ablation of the Sp7 gene while osterix was missing from Runx2 knockout mice 
suggesting that osterix is downstream of Runx2 and depends on Runx2 in order to be expressed.   
 
Osteocytes 
As mentioned, osteoblasts can transform into bone lining cells, but besides this they have two 
options: apoptosis or become osteocytes (M. B. Schaffler, O. D. Kennedy 2012). 
These cells constitutes 90-95 % of the cells within bones and are believed to be the main mediator 
of mechanical signalling in bone while also mediating signalling coming from elsewhere such as 
endocrine or paracrine pathways, reviewed by (L. F. Bonewald 2011;J. Klein-Nulend et al. 2012;M. 
B. Schaffler, O. D. Kennedy 2012). The osteocytes reside within small lacunas in the calcified bone 
matrix where they project long dendritic cell processes out through small channels called canaliculi 
to other osteocytes, cells at the bone surface and nearby blood vessels. The dendrites give them a 
star shaped look, which provides the possibility of crosstalk. This enables them to detect different 
stimuli to which they respond by sending out signalling molecules such as bone morphogenetic 
proteins (BMPs), Wnts, prostaglandin E2 (PGE2), and nitric oxide NO. Furthermore, the osteocyte 
has shown to produce molecular markers such as collagen, ALP, osteocalcin, OPG and RANKL 
(M. B. Schaffler, O. D. Kennedy 2012) adding to the notion of its regulatory potential in bone 
modelling and remodelling.  
 
Bone remodelling  
Bone remodelling (not to be confused with bone modelling – the process occurring in the 
developmental age to shape the skeleton), is a tightly regulated process were osteoclasts and 
osteoblasts cooperate to degrade and rebuilt bone, respectively, in equal amounts. This prevents 
microfractures in the bones to develop into genuine fractures. Bone remodelling can be categorized 
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Figure 1: View of an active BMU under physiological conditions OCYs = Osteocytes, OCs = Osteoclasts, BMU = Basic multicellular 
unit, OBs = Osteoblasts, LCs = Bone lining cells. (adapted from (Baron & Hesse, 2012) 
Figure 2: Same view as figure 1, but under osteoporotic condition 
into four phases: activation, resorption, reversal and formation (R. Tamma, A. Zallone 2012;H. M. 
Frost 1985). First step involves the activation and resorption phases where osteoclast precursors are 
recruited followed by differentiation and activation of mature osteoclasts thus starting resorption of 
bone, which additionally requires maintenance. The latter phase continues for about three weeks in 
human bone followed by the reversal period where resorption is inhibited, osteoclasts undergo 
apoptosis and osteoblasts are recruited and differentiate. In the last phase, the resorbed surface is 
prepared for bone formation where new bone is formed and eventually this site will go into 
quiescence. The process of generating bone is a very slow process, which results in the long 
duration of the last phase taking about three months in humans. The whole process takes place 
within a basic multicellular unit (BMU) (figure 1), where the process of activation proceeds into 
resorption after which reversal and formation takes over ending in formation and finally the finished 
new bone matrix (R. Tamma, A. Zallone 2012;H. M. Frost 1985).      
 
 
 
 
 
Osteoporosis 
Baron and Hesse (R. Baron, E. Hesse 2012)  have defined osteoporosis as “low bone mineral 
density associated with skeletal fractures secondary to minimal or no trauma, most often involving 
the spine, the hip, and the forearm” as a “consequence of an unbalanced bone remodelling process 
with higher bone resorption than bone formation.” This is illustrated in figure 2 where a BMU is 
shown in osteoporotic circumstances depicting more osteoclasts and fewer osteoblasts when 
compared with figure 1 thus visualizing the higher level bone resorption characteristic of 
osteoporosis.  
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Burr et al theorized in a perspective review that osteoporotic fractures might occur as a result of 
positive feedback between damage accumulation and damage repair (D. B. Burr et al. 1997). In 
general terms the production of more microfractures as a result of weaker bone structure, meant an 
increase in BMU targeting these sites for remodelling. However, the fact that remodelling must start 
with resorption before formation implies that more and more microfractures leads to more and more 
resorption pits ultimately weakening the bone thus resulting in an increased risk of fractures.   
 
P2 receptors with emphasis on the P2X7 receptor 
Discovery of ATP in cell signalling started in the early 70s (G. Burnstock et al. 1970;G. Burnstock 
1972). Then a further discovery of two distinctive purinergic receptors called P1 and P2 responding 
to adenosine and ATP respectively (G. Burnstock 1980) ended in the proposed existence of two 
separate P2 receptor families called P2Y and P2X (G. Burnstock, C. Kennedy 1985). These were 
the first steps leading the way - though not without difficulties (G. Burnstock 2012), for the future 
importance of these receptors and the discovery of their widespread localization throughout the 
various tissues in the body including bone (R. M. Rumney et al. 2012).   
Though stated in 1980 that P2 receptors respond to ATP, the P2Y receptor family consisting of 
eight subtypes (P2Y1, P2Y2, P2Y4, P2Y6, P2Y11-14), also respond to ADP, UTP or UDP-glucose, 
while the P2X receptor family including seven subtypes (P2X1-7), only respond to ATP (G. 
Burnstock 2007). Upon activation, P2Y receptors respond in a G-protein coupled manner while 
P2X receptors being a ligand gated ion channel, exchange ions channels.   
Centring now on the P2X7 receptors, which have some characteristic properties in that they need a 
higher concentration of ATP to be activated (1mM). Furthermore, they also respond differently 
when affected for a long time by opening up as pores enabling larger molecules up to 900 kD to 
enter or exit the cell (R. A. North 2002;B. S. Khakh, R. A. North 2006).  
In bone, the role of P2X7 has been demonstrated by means of knockout (KO) mice lacking the 
P2X7 receptor gene (H. Z. Ke et al. 2003). Though no involvement in longitudinal bone growth 
was found, the general circumference and content of both cortical and trabecular bone was 
decreased, caused in part by a decreased number of osteoblasts while osteoclast numbers increase.     
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Because of its particular features, this receptor has been associated with membrane blebbing (N. 
Panupinthu et al. 2007) where ATP supposedly could be transported out of the cell to act in its 
immediate milieu as an autocrine or paracrine mediator (M. Romanello et al. 2005). Consequently, 
in coherence with blebbing, the P2X7 has also been associated with apoptosis (E. Adinolfi et al. 
2005).    
The three SNPs used in this project 
The expression “single nucleotide polymorphisms” implies a definition saying that one percent or 
more of the population has to carry this point mutation in order to call it a polymorphism. 
The mutation occurring for SNP 307 yield a highly positively charged arginine to be replaced by an 
uncharged glutamine. Furthermore, it was found to be situated in the ATP site of the receptor, 
which explained the lack of both channel and pore function when stimulated (B. J. Gu et al. 2004). 
Fortunately, this SNP is only prevalent in one percent of the population (A. Wesselius et al. 2011), 
thus only just covering the definition of an SNP.  
By measuring calcium influx and ethidium bromide intake of recombinant HEK293 cells (G. 
Cabrini et al. 2005) confirmed a functional increase in the P2X7 receptor activation for SNP 155 
consistent with a gain-of-function SNP. This functional gain comes from the amino acid change of 
histidine to tyrosine. The prevalence of this SNP is very close to that seen for WT, in fact (A. 
Wesselius et al. 2011) reports it as being 50%.  
Using site directed mutagenesis (S. Roger et al. 2010) mutate and transfect HEK293 cells with the 
348 SNP among others, in order to determine the functional effect of the P2X7 receptor as a result 
of the mutation. They confirm a gain-of-function SNP when examining the 348 SNP both in 
channel and pore forming analysis. This SNP is a well-known gain-of-function SNP where an 
alanine is changed to threonine, and though not as wide spread as the 155 it is still found in 29 % of 
the population (A. Wesselius et al. 2011). 
As mentioned in the introduction, loss- or gain-of-function SNPs in the P2X7 receptor gene has 
been associated with an increased or decreased risk of developing osteoporosis respectively, in post-
menopausal women, observed by (N. R. Jorgensen et al. 2012). This was a cohort study of Danish 
post-menopausal women enrolled in the Danish Osteoporosis Prevention Study where association 
between SNPs to bone mass and fracture incidence was investigated. They found an increased rate 
of bone loss for the 307 SNP and a conversely protective effect on fracture incidence for the 348 
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SNP. In line with this, a cohort study on Scottish post-menopausal women participating in the 
Aberdeen Prospective Osteoporosis Screening Study (APOSS), found association of 307 with a 
decreased lumbar spine BMD (A. Gartland et al. 2012). More recently, a further cohort study of 
Dutch fracture patients supported the Danish and Scottish studies (A. Wesselius et al. 2013). An 
association was found for 348 with an increased BMD value for the lumbar spine in the Dutch 
patients.  
As reviewed by (A. Wesselius et al. 2011), the presence of haplotype blocks whereby at least two 
SNPs are present in the P2X7 receptor gene can alter the functional phenotype of the P2X7 
receptor, in ways that is inconsistent with the original functional characteristics of certain SNPs. 
This is for instance seen when 155 abrogate the loss-of-function effect of another SNP. 
Furthermore, the joint expression of 348 with another specific SNP enforce the gain-of-function 
effect seen by 348 to an extent beyond the ability of the 348 itself (A. Wesselius et al. 2011). 
Additionally, as reviewed by Sluyter and Stokes (R. Sluyter, L. Stokes 2011), the P2X7 receptor is 
found throughout the tissues of the body, such as the nervous system, blood cells, pancreas and of 
course bone – to name a few. Within the gene coding for the P2X7 receptor, as many as 686 single 
nucleotide polymorphisms (SNPs) have been found – though most are silent mutations, 28 are not, 
and can thus have pathological implications. These include - besides bone disorders - infectious 
diseases, inflammatory disorders, cardiovascular disorders, malignancies and psychiatric disorders 
(R. Sluyter, L. Stokes 2011) with the three SNPs included in this project all found to some extent in 
the various anamnesis of these diseases. 
 
Aim  
The aim of this study is to investigate the cellular effects of P2X7 receptor SNPs 155, 307 and 348 
in the osteoblast cell line ROS 17/2.8 in order to support associations of these SNPs in the P2X7 
receptor and the risk of developing osteoporosis.   
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Materials and methods 
The experiments in this report can be roughly outlined in three steps, the first being site-directed 
mutagenesis where SNPs are induced into the gene of interest, namely P2X7 – while sitting in a 
plasmid. This is done by designing a set of primers around the site destined to be mutated. The 
primers (consisting of about 20-40 bases) only varies from the template strand in one specific base 
thus, if successful, they introduce a different base than in the WT gene.  
The second step is transfection where the cell membrane stands as a barrier to the plasmids. The 
plasmid now containing a mutated P2X7 gene is therefore made lipophilic in order to be able to 
enter the cell.  
Third and final step is testing the effect of the SNPs using expression of different bone markers 
such as Runx2, osteopontin and others by means of Real-time PCR and additionally test the 
receptor function using a calcium assay.    
 
Cell treatment in general 
Growth and maintenance 
ROS 17/2.8 (from now on referred to as ROS) cells were thawed from -140oC and maintained in 
DMEM containing 1% Glutamax (100x, Invitrogen), 1% Penicillin (10.000 Units/ml, Life 
Technologies)/Streptomycin (10.000µg/ml, Life Technologies), while being passaged when 
confluence reached 90-95% using trypsin (10x, Invitrogen).     
 
Counting cells 
Cells were counted using a Neubauer chamber where both counting areas - added 10 µl cell 
suspension in each, were counted.  
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In vitro site-directed mutagenesis  
Principle:  
The full impact of a single point mutation in the sequence of a gene can be hard or even impossible 
to predict. Therefore, a method for inducing single base-pair changes is invaluable when 
researching functional changes as a result of amino acid substitutions or deletions. Site-directed 
mutagenesis offers the possibility of inducing a stable point mutation that can later be analysed 
using different assays.  
The first step in site-directed mutagenesis is the synthesis of the mutant 
strand where the DNA template is denatured, a mutagenic primer containing 
the desired mutation is annealed and incorporated into the DNA by extension 
using a DNA polymerase (see figure 3A).   
Next, the parental DNA template is digested by DpnI enzyme, which only 
digest methylated, and hemimethylated DNA (see figure 3B). 
Finally, the plasmid is transformed into competent bacterial cells for nick 
repair (see figure 3C).  
The Plasmid contain a selection marker – an antibiotic, often ampicillin 
which renders the bacteria resistant to this antibiotic thus killing any other 
bacteria, be it competent cells unable to take up the plasmid, or 
contamination.  
 
Materials: QuickChange Lightning Site-directed Mutagenesis Kit from Agilent Technologies 
#210519 (30 reactions) – see “materials provided” in said protocol.  
 
Procedure  
Plasmid pcDNA 3.1+ was kindly provided by Elena Adinolfi  with the gene of interest (GOI) 
namely P2X7, already inserted (E. Adinolfi et al. 2010). Induction of SNPs were done according to 
instructions by the manufacturer. In brief, a primer pair for each SNP were constructed – see table 2 
Figure 3 
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Table 1: Cycles used for insertion of SNPs. These cycles and temperatures are used for all three SNPs (155, 307 and 348). 
for sequences, and introduced into the GOI using a PCR machine. The reaction was prepared in 
tubes containing reaction buffer (5µl; 10x), dsDNA template (40ng), forward and reverse primers 
(125ng), dNTP mix (1µl), QuickSolution reagent (1,5µl) and H2O (up to 50µl) before adding 
QuickChange Lightning Enzyme (1µl). Afterwards the following cycles outlined in table 1 were 
used.  
Segment Cycles Temperature Time 
1 1 95oC 2 minutes 
2 18 95oC 20 seconds 
60oC 10 seconds 
68oC 4 minutes 
3 1 68oC 5 minutes 
 
When the cycling reaction was complete Dpn I restriction enzyme (2µl) was added and new tubes 
was prepared containing XL 10-Gold ultracompetent cells (45µl), β-ME mix (2µl), Dpn I-treated 
DNA (2µl) and preheated NZY+ broth (45µl) which was put on plates added ampicillin in order to 
pick out transfected cells by ampicillin selection.     
In order to verify the insertion of the SNPs a sequencing of the GOI was ordered – see method 
below. When more plasmid was needed of a given SNP, propagation was administered using 
Maxiprep – see method below, and another sequencing was ordered to check for any potential 
errors that might occur during propagation.      
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SNP Sequence  
489C>T 
(155) 
Forward 
Reverse 
 
 
CCGGAAGGTGTGTAGTGTATGAAGGGAACCAGAAGACC 
GGTCTTCTGGTTCCCTTCATACACTACACACCTTCCGG 
946G>A 
(307) 
Forward 
Reverse 
 
 
CAATGTTGAGAAACAGACTCTGATAAAAGTCTTCGGGATCCG 
CGGATCCCGAAGACTTTTATCAGAGTCTGTTTCTCAACATTG 
1068G>A 
(348) 
Forward 
Reverse 
 
 
CGGTCTGGCCACTGTGTTCATCGA 
TCGATGAACACAGTGGCCAGACCG 
Table 2: Design of primers used in site-directed mutagenesis.  
 
Maxi-prep  
This method was used to propagate plasmid when needed. The procedure was followed according 
to manufacturers instructions except at first when 150 ml overnight culture prepared one day in 
advance was divided into 50 ml aliquots in 50 ml tubes and centrifuged for 20 min. at 4oC at 4700g. 
Afterwards the supernatant was discarded and pellet resuspended in 3,4 ml P1 to be collected in one 
joint tube for further execution of the procedure as described by manufacturer.   
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Sequencing 
1 µg of each SNP or WT was sent to Eurofins for sequencing  
1 primer set was provided by Eurofins designed to work with the plasmid pCDNA 3.1+ and one 
was designed to check for errors beyond the 1000 bp for witch the normal DNA polymerase can 
reach (see table 3 for primer details).  
Primer Design Sequence 
pcDNA3_for Eurofins GGCTAACTAGAGAACCCACTG 
pcDNA3_rev Eurofins GGCAACTAGAAGGCACAGTC 
pcDNA3,1+ forward Barakat Ali and Jan 
Larsen 
 AAACAGAAGGCCAAGAGCAGCG 
pcDNA3,1+ reverse Barakat Ali and Jan 
Larsen 
AAGTCCATCGCAGGTCTTGG 
Table 3: Primers used in sequencing of gene inserted into pcDNA3,1+ plasmid 
Bioedit was used to compare the mutated sequence to that of WT found at NCBI (GenBank: 
Y09561.1) in order to confirm insert of SNPs 
Chromas Lite was used to check for the likelihood of individual bases being sequenced.  
 
Transfection 
Principle 
The dilemma posed by transfection is how to get DNA across a lipid bilayer into a cell. It is a 
matter of how to get the DNA lipophilic in order to cross the membrane, then free itself from this 
lipid capsule in the cytoplasm and finally enter the nucleus, reviewed by (S. Chesnoy, L. Huang 
2000). The method used is a Cationic Lipid-Mediated Transfection. The cationic lipids are 
composed of three parts: a hydrophobic anchor, a linker and a cationic head, producing an 
amphiphilic compound that interacts with plasmid DNA to create a lipid-DNA complex.  
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The lipid-DNA complex enters the cytocol by means of endocytosis, which is believed to be the 
primary pathway of entry. The cell membrane has different negatively charged glycoproteins and 
glycolipids in some cases including a ligand, but if that is not the case, interaction of the lipid-DNA 
complex and the membrane depends on electrostatic forces (S. Chesnoy, L. Huang 2000).   
Once inside the cell, the DNA has to dissociate from the lipids in order to be functional. It is 
believed that this happens by destabilizing the endosomal membrane thought to happen when 
anionic lipids flip-flop from the cytosolic facing membrane to the inward facing membrane 
interacting with cationic lipid to create a neutral charge, thus disrupting the membrane to release the 
DNA (S. Chesnoy, L. Huang 2000).  
  
Pilot experiment transfection with Green Fluorescent Protein (GFP) 
pmaxGFP plasmid kindly provided by Louise Torp Dalgaard is used for this experiment. 
This experiment is executed in order to determine the rate and extent of plasmids being taken up by 
the ROS cells and transcribed. 
Method used for Lipofectamine 2000 from Invitrogen Life Technologies. 
To try different combinations of Lipofectsamine 2000 and plasmid in order to find an optimal 
amount of these compounds, different mixtures of the two was applied on a 24 well plate as 
indicated in table 4. The day before transfection, the 24 well plate is prepared with cells in amounts 
designed so that 80 % confluence is reached at the time of transfection. 
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µg plasmid 
µl 
lipofectamine  
0,2 0,4 0,6 0,8 1,0 1,2 
1 Normal 
cells with 
no 
transfection 
    Normal 
cells with 
no 
transfection 
2       
3       
4 Normal 
cells with 
no 
transfection 
    Normal 
cells with 
no 
transfection 
Table 4: Outline of a 24 well plate indicating different variations of Lipofectamine and plasmid volumes 
Preparation before transfection in brief: Lipofectamine and plasmid was mixed separately in MEM 
only added Glutamax and incubated at room temperature for five minutes, then mixed together in a 
pattern fitting the concentrations outlined in table 4 for further incubation at room temperature for 
twenty minutes and then added to the cells.   
 
Transfection of wild type, empty and mutated plasmids 
Plasmid and Lipofectamine volumes are added according to guidelines from manufacturer – see 
table 5 for details.   
Transfection was performed as described for GFP after which plates/wells are left to incubate 
before analysis begins. Table 5 outlines how transfection was performed regarding different 
parameters. 
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Analysis BZATP  Transfection 
time 
No. 
of 
platet 
cells  
Well/plate 
used 
Area  Plasmid Lipofectamine 
2000 
MEM  
RNA 
purification 
for qPCR 
Yes 48 hours 1 x 
106 
60 mm 
NUNC 
plates 
20 
cm2 
8 µg 20 µl 0,5 µl 
x 2 
Protein 
purification 
for 
Western 
blot 
No 48 hours 2 x 
106 
100 mm 
NUNC 
plates 
60 
cm2 
24 µg 60 µl 1,5 µl 
x 2 
Ca2+ assay Yes 48 hours 5.000 96 NUNC 
wells 
0,3 
cm2 
0,2 µg 0,5 µl 25 µl 
x 2 
Table 5: ATP = Incubated for one hour prior to analysis, Transfection time = Incubation time after transfection, No. of plated cells = 
Number of cells added to each plate/well one day prior to transfection in order to reach confluence of 80 %, MEM = Volume of MEM 
(only added Glutamax) used to mix plasmid and Lipofectamine 2000, first separately then together (indicated by x 2) 
 
Analysis 
Western blot 
Principle 
Briefly, western blot presents a way of visualizing a protein of interest. Starting out with a complete 
protein lysate from a population of cells, the protein of interest is singled out by means of a primary 
antibody binding with high affinity to a few amino acids known as the epitope. Naturally, this 
antibody is produced against the organism in question exemplified by a mouse-anti human antibody 
where the protein of interest is of human origin. Firstly though, the proteins are separated on an 
SDS gel and transferred to a nitrocellulose membrane in order to separate the proteins, thus 
exposing the epitope. Then primary antibody is added along with bovine serum albumin, which acts 
as a blocking buffer inhibiting unspecific binding which might arise as ionic forces between the 
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primary antibody and proteins. Next, a secondary antibody produced against the species from where 
the primary antibody originated, in this example a mouse, exemplified as a donkey-anti mouse 
antibody. By means of a horseradish peroxidase conjugated detection system, the now bound 
protein-primary-secondary antibody complex can be visualized.   
 
Procedure 
ROS cells, transfected as described for 10 cm plates (see also table 5) were used. The cells were 
lysed using radio-immunoprecipitation assay (RIPA) buffer with phosphatase and protease-inhibitor 
(50mM Tris pH 7,5; 150 mM NaCl; 1 mM EDTA; 50 mM beta-glycerolphosphate; 1% NP-40; 
0,1% deoxycholate; 0,1% SDS; 0,5% Triton X-100). The protein samples were quantified using 
Biorad DC kit (Reagent S, A, A’ and B (cat#:500-113, -114, -115)), separated on SDS 
polyacrylamide gels and transferred to nitrocellulose membranes. Membranes were incubated with 
primary antibody for human P2X7 receptor produced in rabbit (Sigma-Aldrich) at 1:200 ratio, 
followed by incubation with a horseradish peroxidase (HRP)-conjugated secondary antibody for 
rabbit IgG from donkeys (GE Healthcare) at 1:40.000. Protein expression was visualized using 
enhanced chemiluminesence (ECL) SelectTM Western Blot Detection Reagent Kit.   
 
Gene expression using Reverse transcription quantitative PCR (RT-qPCR) 
Principle  
This method is used to give a relative quantitative expression estimate of the transcription of a 
target gene. For this method DNA or rather complementary DNA (cDNA) is used. cDNA is 
produced separately by reverse transcribing total RNA isolation (two-step RT-PCR). RT-qPCR uses 
the well-known end-point polymerase chain reaction (PCR), only here, the PCR is carried out in 
real-time thus enabling the possibility of surveying the PCR process as it happens rather than the 
old end-point analysis where the target gene is first analyzed at the end of the reaction. RT-qPCR 
enables the quantification of the transcription of the target gene. The measure of the target gene in 
question is performed by using specific primers and fluorescent probes, which emit a signal for each 
copied pair of cDNA strands belonging to the target gene. The reporter system consist of two dyes 
sitting on a Taqman probe where one dye quenches the other as long as they are in close proximity. 
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When the PCR reaction starts, a pair of designed primers anneal to their targets at either ends of the 
target gene while the Taqman probe find its target in-between the two primers. When the DNA 
polymerases at either primers starts copying the DNA along the two strands, they get closer to each 
other and the probe. When they encounter the probe, the polymerase is fitted with exonuclease 
activity whereby the probe is split up in its individual nucleotides. The reporter dyes on the probe 
are now separated and as a result the quenching stops whereby the unquenched dye emits 
fluorescence. Another reporting method is the SYBR Green, but it will not be covered here. The 
reaction process generates the well known amplification curve of PCR consisting of an exponential 
increase at first because sample, primers/probes and substrate (dNTPs) are in excess. This is 
followed by a linear increase where the enzymes have reached their max potential. Finally, the 
curve levels out in a plateau because one or more limiting factors such as the pimers/probes or 
substrate have run out.   
There are two ways of analyzing the quantitative data from the RT-qPCR an absolute and a relative. 
The absolute method requires a standard curve and is rarely used because it is not often you need 
the exact number of initial copies of a gene. The relative quantification method is used when for 
instance a target gene is compared for WT and a mutated allele. This method provides an accurate 
estimate of the initial copy number of template. For the relative method, the gene expression is 
adjusted by comparing it to an endogenous control which must be equally expressed between 
samples and have an approximate equal amplification level as the sample gene. In the course of 
PCR amplification, the amount of PCR product has to reach a threshold before being regarded as a 
valid amount higher then baseline. When the threshold has been crossed, the corresponding number 
of cycles needed to reach this, is used to define the threshold cycle (CT). CT is used in the 
calculations of the relative amount of initial template outlined below.  
Calculations of amount of  target, normalized to an endogenous reference and relative to a calibrator 
is given by: 2-ΔΔCT. The difference in threshold cycle of reference (R) and sample (S) is given as 
ΔCT. Including a constant for both R and S divided gives K and with the efficiency of amplification 
(E) we get: XN = K x (1 + E)
-ΔCT where XN is the normalized amount of target. Left is just to divide 
the XN for any sample with the XN for the calibrator (cb) and we get: XN,S/XN,cb = (1 + E)
-ΔΔCT 
where ΔΔCT is ΔCT,S – ΔCT,cb. With the efficiency being close to one we get 2-ΔΔCT, also reffered to 
as the relative quantity (RQ).  
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Genes used in RT-qPCR (Applied Biosystems)  
Rn01512298_m1 Runx2 20 x mix (Runx2) 
Rn01775763_g1 Gapdh 20 x mix 
(Endogenous control) 
Rn01516028_m1 Alpl 20 x mix (ALP)  
Rn0269744_s1 Sp7 20 x mix (Osterix) 
Rn00566386_g1 Bglap 20 x mix 
(Osteocalcin) 
Rn01463848_m1 Col1a1 20 x mix (Collagen 
type 1) (named Col-1 throughout this report) 
Hs00951605_m1 P2RX7 FAM 20 x mix 
(P2X7 receptor gene) 
Rn00561414_m1 Ibsp 20 x mix (Integrin 
binding sialoprotein) 
Rn01483828_m1 Ptgs2 20 x mix (COX-2)
 
Procedure 
ROS cells transfected as described for 6cm plates (see table 5) were exposed to BzATP (100 µM) 
for 1h before total RNA isolation was performed using RNeasy mini kit (Qiagen) following 
instructions by manufacturer. RNA (5 µg) was reverse transcribed into cDNA using RT kit 
(Applied Biosystems) incubating at 25oC for 10 min. then 37oC for 2h and finally 80oC for 5 min. 
A pool of non-transfected ROS RNA, reverse transcribed into cDNA, was used as control.  
Gene expression mix and cDNA mix outlined in table 6 were aliquoted for all cDNA variants 
(control, WT, SNPs and empty plasmid) and for all genes (Runx2, Sp7, ALP, Bglap, Col-1, Ibsp, 
Ptgs2, P2X7 and Gapdh) and stored at -20oC until use. When used, they were thawed, spun down 
and mixed in the plates together with the TaqMan universal 2x PCR Mastermix (Applied 
Biosystems) as outlined in table 7. The plate was quickly spun and put in the qPCR machine.  .  
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Table 6: cDNA = Empty plasmid; WT; SNP 155; 307 or 348, Genes = GAPDH; Runx2; ALPL; BGLAP; SP7; Bglap; Col1a1; Ibsp; Ptgs2 and 
P2RX7. 
 
Plates were prepared according to table 7:  
 1 2 3 4 5 6 7 8 
A GAPDH ALPL SP7 RUNX2 BGLAP GAPDH ALPL SP7 
B GAPDH ALPL SP7 RUNX2 BGLAP GAPDH ALPL SP7 
C GAPDH ALPL SP7 RUNX2 BGLAP GAPDH ALPL SP7 
D RUNX2 BGLAP GAPDH ALPL SP7 RUNX2 BGLAP  
E RUNX2 BGLAP GAPDH ALPL SP7 RUNX2 BGLAP  
F RUNX2 BGLAP GAPDH ALPL SP7 RUNX2 BGLAP  
Table 7: Green = Control (pool of plain ROS cDNA used on every plate), Blue = Sample 1 (one of the SNPs, wt or empty plasmid 
transfections which were all run 5 times for each gene), Red = Sample 2 (one of the SNPs, wt or empty plasmid transfections which 
were all run 5 times for each gene). 
 
 
Per reaction Total volume Gene expression 
mix 
cDNA mix qPCR mix 
2x qPCR 
mastermix 
10 µl   10 µl 
H2O 7 µl 4 µl 4 µl  
cDNA 2 µl  1 µl  
Gene Assay mix 1 µl 1 µl   
Total 20 µl 5 µl 5 µl 10 µl 
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Calcium Imaging assay on NOVOstar 
Principle 
The importance of calcium signalling has been greatly enhanced by the of a Fluorometric Imaging 
Plate Reader (FLIPR). This enables a quick, easy way of measuring intracellular calcium changes 
after an extracellular signal has been applied. For this experiment the ratiometric dye Fura-2 is used, 
but other similar reporter dyes like the Fura-3, Fluo-4 and others, can be used. Fura-2 is a dual 
excitation dye which uses two levels of excitation; one at 340 nm in a calcium bound state, and the 
other at 380 nm when calcium is unbound, both with an emission at 510 nm. When observing an 
ongoing intracellular calcium measuring assay, two curves are formed: One for the bound calcium 
at 380 nm which is increasing as more calcium interact with Fura-2 and another curve for unbound 
calcium at 340 nm which is equivalently decreasing as a result of less free intracellular Fura-2. 
Subsequently, a third curve is calculated as a 340/380 excitation ratio which form an increasing 
curve as a measure of change in intracellular calcium concentration.  
There is however an issue to overcome. The cell membrane is impermeable to Fura-2. This is 
solved by coupling the Fura-2 to an acetoxymethyl (AM) ester which create a neutral charge of the 
molecule. However this is insoluble in water why it is necessary to add pluronic F-127 that 
solubilize the neutral compound. Once inside the cell, natural esterases inside the cell cleaves this 
bond, thus producing a charged form of the Fura-2 molecule, which is now stuck inside the cell. In 
addition, probenecid is added to prevent leakage of the dye.   
 
Reagents 
Washing buffer: 0,035g probenecid (285,4g/mol) dissolved in 250µl NaOH (0,6N) plus 50 ml 
HBSS++HEPES buffer and pH is adjusted to 7,35. 
Loading buffer: 3 µl FURA-2 mixed with 3 µl Pluronic F-127 all mixed with 1,5 ml washing 
buffer. 
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 1 2 3 4 5 6 7 8 9 10 11 12 
A B - - - - - - - - - - - 
B B NO 
Veh. 
NO 
BZ 
Emp. 
Veh. 
Emp. 
BZ. 
WT 
Veh. 
WT 
BZ. 
WT 
BZ. 
155 
Veh. 
155 
BZ. 
155 
BZ. 
- 
C B NO 
Veh. 
NO 
BZ 
Emp. 
Veh. 
Emp. 
BZ. 
WT 
Veh. 
WT 
BZ. 
WT 
BZ. 
155 
Veh. 
155 
BZ. 
155 
BZ. 
- 
D B + + + + + + + 307 
Veh. 
307 
BZ. 
307 
BZ. 
- 
E - + + + + + + + 307 
Veh. 
307 
BZ. 
307 
BZ. 
- 
F - + + + + + + + 348 
Veh. 
348 
BZ. 
348 
BZ. 
- 
G - ATP ATP ATP ATP + + + 348 
Veh. 
348 
BZ. 
348 
BZ. 
- 
H - - - - - - - - - - - - 
Table 8: Setup of 96 well plates used for Calcium assay. B = Blank, NO = no transfection, Emp. = empty plasmid transfection, WT = 
Wild Type plasmid transfection, 155 = 155 plasmid transfection, 307 = 307 plasmid transfection, 348 = plasmid transfection, Veh. = 
Vehicle, BZ. = BzATP, - = only medium added with no cells, + = wells containing cells that did not undergo any treatment concerning 
the assay.    
Procedure 
Cells were plated and transfected as described in the method section under transfection (see table 5). 
At the day of carrying out the assay, the 96 well plates are prepared by loading with Fura-2 
followed by washing before carrying out the analysis on a NOVOstar where cells are measured 
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under the influence of BzATP (1 mM) for one hour. Wells only containing medium are used as 
blank controls. Wells containing cells not having been transfected are used as negative controls 
while others are used as positive controls when affected with ATP.  
The setup on all plates are shown in table 8 
 
Data processing 
For calcium assays, the change in intracellular calcium concentration for SNPs and empty plasmid 
transfection was compared to WT in a students t-test using the statistical program SPSS  
For RT-qPCR, RQ for SNPs and empty plasmid transfection was compared to WT in a students t-
test using the statistical program SPSS 
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Figure 6: Screenshot from Bioedit showing induction of SNP 
Ala348Thr by the change in bases from a G to an A 
(highlighted) in the DNA of the P2X7 gene. Top sequence = 
WT, bottom sequence = SNP Ala348Thr 
Figure 7: Screenshot from Bioedit showing a supposedly 
missing base (-) in SNP His155Tyr (bottom sequence) 
when compared to WT (top sequence). Bottom sequence 
indicated by dots when bases are identical to top 
sequence 
Figure 5: Screenshot from Bioedit showing induction of 
SNP His155Tyr by the change in bases from a C to a T 
(highlighted) in the DNA of the P2X7 gene. Top sequence 
= WT, bottom sequence = SNP His155Tyr 
Figure 4: Screenshot from Bioedit showing induction of 
SNP Arg307Gln by the change in bases from a G to an A 
(highlighted) in the DNA of the P2X7 gene. Top sequence 
= WT, bottom sequence = SNP Arg307Gln 
Results 
Site directed mutagenesis 
Using the program Bioedit, results from the site directed mutagenesis was obtained. Figure 4, 5 and 
6 depicts the three SNPs used in this project as a print screen from Bioedit showing induction of the 
base changes corresponding to the respective SNP. For SNP 155 C in WT is successfully changed 
to a T. Likewise for SNP 307 a G in WT is successfully changed to an A and finally for SNP 348 a 
G in WT is successfully changed to an A.  
 
 
 
 
 
 
 
 
 
The sequence from Eurofins could at times produce bases seeming to be absent compared to WT. 
Figure 7 show a screenshot from Bioedit were the supposedly missing base in question is illustrated 
as a line. Figure 8 show a screenshot from Chromas lite depicting a chromatogram with a stretch of 
sequence including the missing base in question represented by a space.  
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Figure 8: Screenshot from Chromas Lite depicting chromatogram 
of SNP 155 depicting a supposedly missing base indicated by a 
space (yellow square) 
Figure 9: Picture of pmaxGFP transfected ROS cells 
expressing GFP. Picture taken 24 hours after transfection 
with 0,8 µg pmaxGFP plasmid and 2 µl Lipofectamine (see 
method for more information) 
Figure 10: Picture of pmaxGFP transfected ROS cells 
expressing GFP Picture taken 48 hours after transfection 
using same plasmid and Lipofectamine concentrations as in 
figure 9 (see method for more information)  
 
 
 
 
 
Looking at the chromatogram in figure, it is with some certainty that the missing C depicted in 
figure 7 should have been present according to the colour depiction from Chromas lite.  
 
Transfection 
Pilot experiment transfecting with Green Fluorescent Protein (GFP) 
Pictures showing pmaxGFP transfected ROS cells was taken 24, 48 and 72 hours after transfection 
as depicted in figure 9, 10 and 11 respectively. 
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Figure 11: Picture of pmaxGFP transfected ROS cells 
expressing GFP. Picture taken 72 hours after transfection 
using same plasmid and Lipofectamine concentrations as in 
figure 9 (see method for more information) 
 
 
 
 
 
 
 
 
Pictures of all the wells prepared for this experiment (see method for more information) was taken 
after looking and analysing the amount of GFP expression through an inverse fluorescent 
microscope, but only these three pictures in figure 9-11 are presented as they are representing 
recommended concentrations provided by the manufacturer of plasmid and Lipofectamine. Other 
concentrations of Lipofectamine and plasmid showed similar patterns of expression (data not 
shown) 
 
Analysis 
Western blot 
Throughout experimenting with western blot, there would always be a veil of bands in each lane 
loaded with protein. Therefore, optimization of the method was keen, resulting in examples like that 
seen in figure 12 where to different concentrations of protein is loaded. Though the bands are 
weaker when less protein is loaded, the veil of bands are still noticeable. The problems finally 
culminated in an experiment where only secondary antibody is added as shown in figure 13. This 
revealed the extent of the unspecific binding exhibited by the secondary antibody, even with a 
concentration as low as 1:80.000 where before 1:40.000 was used.  
Initially, the purpose of the western blot was to show the expression of the P2X7 receptor when the 
pcDNA3.1+ plasmid with P2X7 receptor gene inserted was transfected into ROS cells. Figure 12 
and 13 both have a blue arrow where the ladder marker indicate 70 kD, which is the marker closest 
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Figure 12: View of Western blot gel with cell/SNP loaded onto each 
corresponding lane. Blue arrow indicate 70kD where the product of P2X7 
should be just below at 69 kD. For lanes 1-4, 25 µg total protein is added 
while 12,5 µg total protein is added for lanes 5-8. For all lanes, primary 
and secondary antibody are added in concentrations of 1:200 and 
1:40.000 respectively. SaOS2 = SaOS2 cell with no treatment; WT = wild 
type transfection; ROS = plain ROS cell with no treatment; 348 = 348 SNP 
transfection. 
Figure 13: View of western blot gel similar to Figure 12. 
Blue arrow indicate 70 kD to better compare the gel in 
figure 12. 25 µg total protein is added, with primary 
antibody omitted. Secondary antibody is added in 
concentration of 1:80.000. WT = wild type transfection; 
348 = 348 SNP transfection; ROS = plain ROS cell with no 
treatment; EMP = transfection using empty plasmid; 
SaOS2 = SaOS2 cell with no treatment. 
to the expected P2X7 product of 69 kD. However as is evident, the number of bands around the 
point of 69 kD makes it impossible to pinpoint P2X7 in figure 12, and as figure 13 shows, many of 
the bands in figure 12 is most likely a result of unspecific binding.    
 
 
 
 
  
 
  
 
 
QPCR 
This analysis is based on eight genes where expression is show in RQ values, which refers to a 
calculated quantification of the initial concentration of mRNA for each SNP, WT and empty 
plasmid. All statistical significant differences originates from comparison of WT expression of the 
corresponding gene in question. RQ values for each gene and SNP, WT or empty plasmid is 
depicted in figure 14 and the increase, decrease or equal expression of genes for empty plasmid or 
SNPs when compared to WT is depicted in table 9. In this figure and table, the same RQ values and 
difference in expression respectively, are the subject for the forthcoming commentaries regarding 
qPCR.  
When compared to WT, transfecting with an empty plasmid produce a general decrease in 
expression for Runx2, Ptgs2, Ibsp and P2X7 while for SP7, BGLAP, ALP and collagen it produces 
an increased response as depicted in figure 14 and table 9. Surprisingly though, only half namely 
BGLAP, ALP, Ptgs2 and P2X7 produce a significant difference (p-value: 0,029, 0,005, 0,030, and 
0,00007 respectively). In contrast, Runx2, SP7, collagen and Ibsp do not significantly differ from 
WT (p-value: 0,230, 0,514, 0,606 and 0,469 respectively).  
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When using 155, the differences when compared to WT favours increased expression. Runx2 and 
Ptgs2 are the only two where expression is decreased while all others show increased expression. 
Significant differences are found for SP7, BGLAP, ALP and Ptgs2 (p-value: 0,038, 0,042, 0,001 
and 0,019 respectively). In contrast, Runx2, collagen and P2X7 do not produce significant 
differences (p-value: 0,314, 0,319 and 0,938 respectively) while Ibsp show a higher degree of 
tendency toward increased expression (p-value: 0,081).  
Results obtained after comparing 307 and WT, like seen for 155, only produce two genes of which 
decreased expression is observed namely Ptgs2 and P2X7, while Runx2 show equal amounts of 
expression leaving the rest as increased. Significant differences in expression compared to WT are 
seen for SP7, BGLAP, ALP, and P2X7 (p-value: 0,037, 0,030, 0,001 and 0,001 respectively). 
Furthermore, Ibsp show a high degree of increased expression though not significant (p-value: 
0,068), thus producing same tendency as is the case for 155. This leaves Runx2, collagen and Ptgs2 
which did not even approach significant difference (p-value: 0,968, 0,215 and 0,468 respectively).  
Finally, for 348 Runx2 and Ptgs2 show slight decreases in expression when compared to WT while 
expression of collagen is very close to the same as WT. Increase in expression is seen for the rest, 
with many exhibiting significant or close to significant increase. Genes showing significant increase 
include BGLAP, ALP and Ibsp (p-value: 0,004, 0,003 and 0,012 respectively), while SP7 show a 
clear tendency of increase (p-value: 0,055) and Ptgs2 show an equal tendency of decrease (p-value: 
0,060). Left then is Runx2, collagen and P2X7 (p-value: 0,349, 0,840 and 0,155 respectively).   
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Figure 14: Depiction of the relative gene expression shown by RQ. All statistics are based on a students t-test comparing WT to other 
SNPs and Emp. Runx2 encode Runx2 protein, Sp7 encodes Osterix, BGLAP encodes Osteocalcin, ALP encodes Alkaline phosphatase, 
Col-1 encodes Collagen type 1, Ptgs2 encodes Prostaglandin-endoperoxide synthase 2 (COX), Ibsp encodes Integrin binding specific 
protein, P2X7 encodes P2X7 receptor protein. RQ = Relative quantification, * = p<0,05, ** = p<0,01, *** = p<0,001.  
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Gene Empty plasmid SNP 155 SNP 307 SNP348 
Runx2 ↓  ↓  ↔  ↓ 
Sp7 ↑ ↑ * ↑ * ↑ 
BGLAP ↑ * ↑ * ↑ * ↑ ** 
ALP ↑ ** ↑ *** ↑ * ↑ ** 
Col-1 ↑ ↑ ↑ ↔ 
Ptgs2 ↓ * ↓ * ↓ ↓ 
Ibsp ↑ ↑ ↑ ↑ * 
P2X7 ↓ *** ↔ ↓ *** ↑ 
Table 9: Showing effect of BzATP on the expression of bone markers in relation to expression in WT compared to SNPs and Emp. All 
data are taken from figure XX. Significant differences are shown by *. ↓ = decreased expression, ↑ = increased expression, ↔ = no 
change in expression, otherwise all other table explanation is the same as for figure XX. 
  
Calcium assay 
This assay is used to check the functional changes of the P2X7 receptor used in this project when 
the three different SNPs are induced. Statistics are conducted by comparing WT to all other SNPs 
and empty plasmid transfection. This culminates in figure 15, which summarizes the results from 
the calcium assay. Here every vehicle control is depicted next to its corresponding SNP, WT or 
empty plasmid (see method for more information) showing a clear lack of response when applied. 
Furthermore, the statistical results reveal a clear difference between empty plasmid and 307 when 
compared to WT (p-value: 0,000000 and 0,000004 respectively). Moreover, 348 also show a big 
difference when compared to WT, though strictly not significant, but strongly indicating an increase 
in function (p-value: 0,053). In contrast, 155 show no difference of any significance (p-value: 
0,859) only a slight indication of producing a minute increase in response when compared to WT.  
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Figure 15: Data obtained from Calcium assay as described under method (skal uddybes i metode). All samples having been 
affected with BzATP are compared to wt, likewise affected with BzATP. Vehicle controls in replacement for BzATP for each empty, 
wt or SNP transfection are shown in matching colour (no statistics applied to vehicle). Errorbars are shown as standard error of 
the mean  – T. = no transfection; E. = Empty plasmid transfection; wt = wild type; 155 = SNP 155; 307 = SNP 307; 348 = SNP 348; 
Bz = BzATP; V = Vehicle; * = p-value under 0,05; *** = p-value under 0,001   
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Discussion  
Missing bases in sequences 
By using site directed mutagenesis, induction of the 155, 307 and 348 SNPs where achieved in the 
P2X7 receptor gene. A successful mutation however, had to be confirmed be sending a sample of 
the plasmid wherein the P2X7 receptor gene were inserted to be sequenced (see method section for 
further information). However, when results came back from sequencing by Eurofins they often 
revealed one or more missing bases when compared to the known sequence of WT from NCBI. 
These mishaps however, was seen at the far end of the sequencing, where the error probabilities 
would have been higher (J. Shendure, H. Ji 2008;B. Ewing, P. Green 1998). This higher probability 
of error is because the polymerase would have had a higher risk of losing its grip on the parental 
strand (Alberts Bruce et al. 2014) thus decreasing the likelihood of an actual missing base. Using 
Chromas Lite to investigate the error probability in the chromatograms designed to predict the 
sequence of bases (see also figure 8), the supposedly missing bases could in most instances, with 
assistance from Cathy Mitchelmore, be predicted as being present. Finally, a subsequent sequencing 
of the middle of the sequence proved the existence of the supposedly missing bases with a much 
higher prediction value. The latter sequencing was also necessary because P2X7 is too long a gene 
to be sequenced by only one pair of primers. This is caused by the fact that the gene is 1853bp long 
plus about 100bp added from the pcDNA 3.1 plasmid at either ends of the insert where the primers 
attach. Therefore it is not possible for the polymerase to stay on the parental strand for the whole 
stretch of DNA without losing its grip as a consecuence of only producing about 1000bp (J. 
Shendure, H. Ji 2008) before letting go.  
As a side note, two more SNPs were included in experiments of site directed mutagenesis, but due 
to inability of inducing the intended point mutation, they were eventually cancelled.  
 
Transfection efficiency  
The transfection method in this project leads to a transient uptake of plasmid in the cells opposed to 
a stabile transfection. In order to investigate what this means in terms of quality and quantity of 
gene expression in transfected ROS cells a pilot experiment was carried out using GFP as the 
reporter gene. This showed expression of GFP after just one day, but only in about 10-20% of cells. 
After two days, more cells were fluorescing as a result of successful transfection, but still only at 
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about a rate of 40%. However, at three days post-transfection the cells showed signs of decreased 
expression revealed by less bright fluorescence and with about 30% cells involved.  
This experiment led to the conclusion that 48 hour incubation time post-transfection was the 
optimal choice before commencing any analytical experiments. However, another issue to be taught 
from this experiment was the fact that not every cell is expressing the same amount – if any, of the 
gene of interest hence leading to potential different outcomes of analyses whether it be functional or 
analytical.  
Others (G. Escher et al. 2005) have experimented in transient transfections using Lipofectamine 
2000 among other, but found low efficiency of transfection. Using macrophages as their target cell, 
they only accomplished a 7% success rate in their transfection. The authors used other methods of 
transfection finding DEAE-Dextran to be the most effective albeit only achieving 10% cells positive 
for transfection. This low transfection rate however was found to be caused by methylation of the 
cytomegalovirus plasmid promoter, also present in the pmaxGFP and pcDNA 3,1+ plasmid with the 
latter being the main plasmid for experiments in this project. When implementing demethylation the 
rate of transfection rapidly increased to over 95% strongly indicating a use for epigenetics when 
transiently transfecting cells.   
Experiments in this project is with all likeliness not relying on outcomes from a 7% transfection rate 
based on the results from GFP pilot experiment, qPCR for P2X7 receptor gene expression and 
calcium assay (with the latter two being discussed later). Still however it is noticeable that not every 
cell is expected to be transfected and is therefore potentially working against the aim of this project, 
which is to investigate the impact of introducing P2X7 to a cell lacking said receptor while also 
looking at changes following an induced SNP in this gene.  
An attempt to generate a stabile transfection was also carried out during this project. In brief it 
implied cutting out the P2X7 insert and relocating it to another retroviral plasmid called pMSCV-
puro. However further progress was eventually brought to a halt because of unforeseen implications 
due to inconclusive results when applying restrictive enzymes to the supposedly ligated insert and 
plasmid in order to verify a complete construct.     
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Choice of cell line 
The ROS cell used in this project (R. J. Majeska, G. A. Rodan 1982) was initially not the first 
choice of cell line. Because the gene of interest used in this report (P2X7 receptor gene) is the 
version found in humans, an optimal cell line for expression of this gene would be of human origin. 
Therefore, the cell line known as HOBIT (P. E. Keeting et al. 1992) was acquired. Although 
looking promising because of its reported lack of P2X7 receptor gene expression by Wesselius et al 
(A. Wesselius et al. 2011), the cell line refused to grow in media same medium used for the ROS 
cells reported here and reported by others to induce HOBIT cell growth (A. Pines et al. 2003). The 
HOBIT cells would simply not stick to the surface of growth plates. Moreover, Pines et al 
successfully grows ROS cells in the same medium, adding to the puzzle as to why our HOBIT cells 
would not comply.  
When finally choosing the ROS cell line it was on the basis that it was readily available in the 
laboratory and according to Niklas Rye Jørgensen did not contain P2X7 gene expression. 
Furthermore, Jørgensen et al found that ROS did not contain any P2Y2 receptors (N. R. Jorgensen 
et al. 1997), and may in fact only contain a few - if any, P2 receptors based on a lack of any calcium 
wave response when affected with ATP or UTP.    
 
Unspecific binding in western blot 
The Western blot analysis is used widely to confirm the presence of a protein in a cell. In our 
laboratory, a working protocol for P2X7 protein has been used with success for a while. This led to 
the belief that it was a somewhat easy method to carry out though of course a few corrections and 
optimizations was expected. As is evident when looking at figure 13, is the unspecific binding of 
the secondary antibody that led to the discontinuation of this analysis.  
Other methods designed to visualize protein was attempted including in vitro protein synthesis and 
immunostaining (mentioned in more detail later), but to no avail (results not shown). While this led 
one to theorize that, no P2X7 protein was being expressed, due to lack of transcription of DNA or 
translation from mRNA, other results, to be discussed later in this project, strongly oppose both 
theories.  
If time had allowed, the next step in optimization of the western blot would first and foremost be a 
change in antibody. Changing the secondary antibody is a given, but since no clear band, indicating 
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the presence of P2X7 in transfected cells were ever present, a change in primary antibody would 
also be preferable.  
 
Impact of SNPs induced into P2X7 gene in ROS cells 
The P2X7 receptor has a role to play in bone formation and in the development of osteoporosis seen 
among other via mutations in the gene found throughout the population thus having characteristics 
of SNPs. As a result hereof, this current project sought to shed light on the impact of these SNPs in 
vitro in osteoblasts. This was attempted by means of site directed mutagenesis of the P2X7 WT 
gene, transfection of plasmid containing SNPs of the P2X7 receptor gene into ROS cells and a 
subset of assays applied to these transfected cells.   
 
Affirmation of successful transcription and expression of P2X7 
When successfully transfected, a detectable protein is still essential. Though complications occurred 
during execution of western blots, results from the calcium assay and qPCR confirm the presence of 
a functional receptor. This functionality comes primarily from the calcium assay where BzATP is 
applied to the transfected cells thus targeting the P2X7 receptors specifically (J. S. Wiley et al. 
1996) – though other P2 receptors have been found to also respond to BzATP (B. R. Bianchi et al. 
1999). The purple bars in figure 15 illustrate the impact of BzATP and vehicle on the WT P2X7 
receptor when transfected into ROS cells. When vehicle is applied, the resulting calcium response is 
close to that seen when an empty plasmid is transfected as seen by the yellow bars in figure 15. In 
contrast, WT show a significant response compared to empty plasmid transfection when BzATP is 
applied. Furthermore, the lack of response when untransfected cells have BzATP administered as 
seen for the grey-blue bar marked –T. in figure 15, demonstrate that the response seen in WT when 
BzATP is administered is with all probability a result of P2X7 receptor activation.   
For qPCR, though not evidently showing a functioning protein, the P2X7 receptor gene is shown to 
be transcribed as seen in figure 14 under P2X7 were WT show significant change in expression 
compared with empty plasmid transfection.  
Combined, these results strongly indicate the complete transcription of the P2X7 receptor gene and 
its subsequent functional expression on the surface of ROS cells.  
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In addition, other approaches was attempted in order to visualize the P2X7 receptor (mentioned 
earlier).These attempts included in vitro protein synthesis which takes advantage of the 
bacteriophage T7 promoter incorporated in the plasmid prior to the inserted gene.  Thereby, all that 
needs to be added is a T7 RNA polymerase to produce mRNA and ribosomes together with amino 
acids to subsequently translate the mRNA into protein. Due to incorporation of some radioactive 
amino acids, the produced protein can be visualized. Despite the easy setup of this method, no 
protein was visualized in the end. However, the easy setup also meant a limited degree of 
optimization thus rapidly causing a natural cessation of further progress of this method.  
Another possibility of visualizing the P2X7 protein presented itself via immunostaining where ROS 
transfected with P2X7 are targeted by primary antibody for human P2X7 and a subsequent 
secondary antibody produced against the primary antibody visualizes this specific reaction. 
However, following difficulty discriminating sample results from those of the negative control (data 
not shown), this method was also put on halt.  
 
Functional changes of the P2X7 receptor 
As a result of SNPs induced into the P2X7 gene, the functional calcium assay, by means of calcium 
waves, has the opportunity to show different outcomes in response to changes in the receptors 
conformational change. Results obtained when finding and characterizing the three SNPs used in 
this report by others (G. Cabrini et al. 2005;B. J. Gu et al. 2004;C. Sun et al. 2010) (155, 307 and 
348), provide a preconceived hypothesis of the outcome since a gain- or loss-of-function has 
already been established. Consequently, the SNPs should either result in an increase or decrease in 
calcium response in concordance with their gain- or loss-of-function phenotype. Fortunately, for 
two of the SNPs, results presented here were as expected showing a significant increased response 
compared to WT when the gain-of-function SNP 348 was applied and an almost complete lack of 
response when the loss-of-function SNP 307 was applied.    
Concerning SNP 155, the results from Cabrini et al indicating this SNP as producing a gain-of-
function effect on the P2X7 receptor was not possible to confirm. In fact, the results from our 
calcium assay suggest a functional output of the P2X7 receptor like that seen for WT.  
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Gene expression in relation to SNPs 
In order to estimate the impact the three SNPs had on osteoblast function in relations to their 
functional role of producing bone, a number of genes were examined for changes in expression.  
As mentioned earlier, Runx2 and osterix (encoded by the SP7 gene) are both involved in the 
differentiation of preosteoblasts toward a more mature osteoblastic lineage. However as also stated, 
osterix is dependent on Runx2 in order to be expressed. In this regard, the higher expression seen 
for osterix while Runx2 meanwhile remain close to unchanged (see figure 14 and table 9) is 
therefore in line with the literature. In contrast to our results, others (A. Costessi et al. 2005) 
showed an activation of Runx2 mediated by extracellular nucleotides in the HOBIT cell line when 
stimulated with ATP. However, they did not show which P2 receptor is activated in this event, only 
that they suspect the P2Y receptors to be involved. Meanwhile, Syberg et al (unpublished results) 
find a decrease in Runx2 expression when targeting the P2X7 receptor in primary trabecular 
osteoblasts by using BzATP. Although this latter study goes against the results found in our 
experiments where Runx2 seems unchanged in expression, the fact that BzATP was applied for 
three instead of one hour could produce the different outcomes. Together these other studies 
indicate an inconsistent expression pattern of Runx2.  
For Ptgs2, which encode COX-2, figure 14 and table 9 under Ptgs2 indicate an increase in 
transcription when a loss-of-function SNP is applied compared to the two gain-of-function SNPs, 
though all three show a decreased transcription when compared to WT. However these fluctuations 
in Ptgs2 expression - though significant for 155, are minute and with a significant increase in 
expression is seen when empty plasmid is transfected indicate that conclusions should be met with 
caution. Furthermore, when comparing our results to those of Grol et al, they find significant 
increase in relative Ptgs2 gene expression, however they use 300 µM BzATP to activate P2X7 on 
the MC3T3-E1 cell line whereby maximum expression is seen after three hours (M. W. Grol et al. 
2013). Results after one hour are also reported and show only slight increase in expression and that 
is with a three time increase in BzATP concentration compared to our setup. The use of a mouse 
cell line - somewhat resembling rat, and the fact that more BzATP and a longer measurement time 
is applied, indicate that our setup might need revising with the inclusion of higher concentration of 
BzATP and longer measurement time, both preferably with intervals enabling further comparison.     
Osteocalcin (encoded by BGLAP), being a specific osteoblast marker (R. H. Christenson 1997) has 
the opportunity of revealing significant changes in osteoblast function and so does ALP in its role 
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as an important factor in bone production. Following this, figure 14 and table 9, show both the 
BGLAP and ALP genes exhibiting significant change in expression compared to WT, for all SNPs 
and empty plasmid transfection. Furthermore, the loss-of-function SNP show a larger increase in 
expression compared to the two gain-of-function SNPs. In addition, the empty plasmid transfection 
also show significant increase compared to WT for both genes. However it is unexpected that empty 
plasmid transfection resembles the gain-of-function SNPs more than that of the loss-of-function 
SNP seen as the 307 SNP is expected to resemble the phenotype of the empty plasmid transfection 
in concordance with results from the calcium assay. Syberg et al (unpublished results) find a 
significant increase in BGLAP expression while ALP expression did not change significantly when 
affecting primary trabecular osteoblasts with BzATP for three hours. For BGLAP, the contributing 
factor for the difference seen when compared to our results appear to be the time difference. The 
insignificant change in expression for ALP appears to be more similar to the results observed in this 
project because while significant, the relationship between loss-of-function and gain-of-function 
SNPs and the empty plasmid transfection speaks against the expected results.   
Results for Col-1 show no significant changes in expression when SNPs and empty plasmid 
transfection are compared to WT. This is in line with results obtained from (I. R. Orriss et al. 2012) 
who find no change in Col-1 expression when differentiating primary osteoblasts are treated with 
BzATP. However, an increase in expression is seen for mature osteoblasts. Furthermore, an 
increase in soluble collagen is seen for both differentiating and mature osteoblasts. Orriss et al also 
examined ALP levels and found no change in expression for either proliferating, differentiating or 
mature osteoblasts. However, a decrease in activity of 45% of ALP was found for mature 
osteoblasts.  
Bone sialoprotein (BSP) encoded by the IBSP gene was found to have very little research done in 
relations to purinergic receptors, let alone the P2X7 receptor. Only results found, was that of (V. B. 
Ayala-Pena et al. 2013) who investigate the impact of exposing primary osteoblasts to 100µM ATP. 
They subsequently found a significant increase in BSP mRNA expression, with similar results 
observed when stimulated with UTP, thus indicating involvement of P2Y receptors. In relations to 
our results regarding the expression levels of IBSP, the results are difficult to compare seen as our 
results indicate an almost linear increase in expression of the three SNPs when compared to WT 
when listed in ascending order of increase starting with 155, 307 and ending in 348 with the latter 
being significantly different from WT. This is in contrast with the expected being that 307 ought to 
45 
 
have the lowest increase while 155 and 348 were expected to show similar levels of change in 
expression.  
Results from P2X7 receptor gene expression fortunately show lack of expression for the empty 
plasmid transfection. In contrast, WT and all three SNPs exhibit clear expression. However, no 
equal level of expression is observed contrary to the expected result. The significant difference in 
expression of 307 when compared to WT leaves one puzzled, since no obvious explanation can be 
found. This indicates a different level of expression based on the SNP, but this would imply a 
fundamental alteration in the transcription of the gene, not previously observed. In addition, the 
large variance observed for 155 depicted by the standard error of the mean (sem), also indicate a 
varying transcription of this gene caused by this SNP. However, an error in the execution of the 
experiment is more likely the cause of these fluctuations in P2X7 receptor expression. Another 
observation is the far greater rate of expression seen for this gene compared to the bone marker 
genes, but this most likely has its basis in the fact that none of this gene was expressed prior to 
transfection due to the nature of ROS lacking P2X7 receptors, thus making any amount of 
expression seem vast.    
 
Mixed results from qPCR 
Describing the results from qPCR evidently led to a somewhat vague description of the RQ values 
seen in figure 14. Causing it was the fact that a gain-of-function SNP is associated with an increase 
in gene expression and vice versa for loss-of-function SNPs which is far from the rule in these 
results. Furthermore, a lower level of expression was expected for empty plasmid transfection when 
compared to WT, but in contrast, this is only seen for a few genes. Moreover, a significant decrease 
in expression for the empty plasmid transfection is only seen for one gene besides the P2X7 
receptor gene expression.  
Reason for the often minute change in expression of a gene when influenced by a SNP or WT, is 
likely due to the fact that ROS did not contain P2X7 prior to transfection, however the cell thrived 
all the same. This could indicate that a sudden and short-lived induction of the receptor, let alone a 
point mutation in said receptor, had little if any effect on the expression of a gene. Further evidence 
for the small impact delivered by P2X7 receptor and SNPs to gene expression in ROS is to be found 
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in the very narrow range of RQ seen in figure 14 with the exception of P2X7, suggesting that very 
little change in expression has occurred after exposure to BzATP for one hour.  
    
Pathways involved 
Any conclusive remarks are hard to draw based on the results obtained from the qPCR experiment 
due to their inconclusive nature. However, the intention for the results obtained in this report was to 
end with a coherent indicative set of pathways involving P2X7, calcium and the bone markers 
presented in the qPCR results. Others have found P2X7 to activate pathways involving 
lysophosphatic acid that subsequently mediate blebbing in osteoblasts. However, the inclusion of 
the specific markers and shift in calcium concentration used in this report have been hard to put in 
relation to these studies.  
Now, a general model involving P2X7 and pathways related to it, will attempt to be hypothesised. 
When researching pathways related to this study, when dealing with calcium waves, a protein 
dependent on calcium is a good starting point. A calcium sensitive protein phosphatase called 
calcineurin fits this description while additionally being dependent on another enzyme called 
calmodulin which in fact also require calcium, reviewed by (P. G. Hogan et al. 2003). When 
intracellular calcium concentration increase, calmodulin and in turn calcineurin is activated 
followed by dephosphorylation of nuclear factor of activated T-cells (NFAT) that consist of a 
family of five proteins of which four are regulated by calcium/calcineurin (P. G. Hogan et al. 2003) 
and collectively referred to as NFAT. This protein now altered in conformation in order to have 
increased affinity to its target sites in DNA, then relocate to the nucleus where several target genes 
can be transcribed. Observations by (T. Koga et al. 2005) indicate that such target genes could 
involve the osteoblastic bone markers Col1a1 (Col-1 in this report), Ibsp and Bglap. They come by 
these findings through the inhibition of calcineurin and the subsequent inhibition of NFAT activity 
in osteoblasts with a resulting decrease in mRNA expression of these three genes. In contrast, no 
significant change is seen for Sp7 and Runx2 mRNA expression when NFAT activity is inhibited. 
However, a strong correlation is found between NFATc1 (one of the four NFAT proteins in the 
group of five mentioned earlier) and osterix (protein encoded by Sp7) interaction and a subsequent 
increase in the transcriptional activity of osterix, suggesting a cooperative role of osterix and 
NFATc1. Likewise, this cooperation of osterix and NFATc1 is seen by an osterix dependent 
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recruitment of NFATc1 to the Col1a1 promotor. In contrast, the recruitment of osterix is 
independent of NFATc1, but the activity of osterix was found to be dependent on NFAT.  
Koga et al also find a general decrease in bone mass when inhibiting NFAT activity in mice, thus 
indicating a strong correlation between NFAT and bone formation. These results are supported by 
(M. M. Winslow et al. 2006) who find high bone mass and increased osteoblast proliferation in 
mice expressing a constitutively nuclear NFATc1 variant.  
Finally, when including P2X7 as seen for (M. W. Grol et al. 2013), they find a major role for P2X7 
and NFATc1 translocation to the nucleus. By the addition of a range of ATP concentration (0,01- 
1mM) and BzATP (300 µM) they find that, although both ATP in all induce translocation of 
NFATc1 to the nucleus, the event is much more sustained for high concentration of ATP and for 
BzATP while low concentrations of ATP induce transient nuclear localization. Furthermore, they 
confirm the involvement of P2X7 in nuclear translocation by investigating the effect of BzATP and 
ranged concentrations of ATP on primary calvarial osteoblasts isolated from P2X7 knockout mice. 
They find that BzATP and high concentration of ATP mimic the effect seen for low ATP 
concentration namely transient localization of NFATc1 in the nucleus. Furthermore, this transient 
localization was seen in WT primary calvarial osteoblasts when stimulating with low concentration 
of ATP while BzATP and high concentration of ATP elicited the sustained translocation previously 
observed.    
When put in relation to this study, results from the calcium assay suggest that the same results 
should apply for the WT P2X7 receptor when activated by BzATP or high concentration of ATP. 
Furthermore, 348 would have had a significant increased effect on the localization of NFATc1 to 
the nucleus seen as the increased intracellular calcium levels would increase the activity of 
calmodulin and calcineurin. In contrast, 307 would have had minimal - if any, effect on the 
translocation of NFATc1 to the nucleus due to a significant decrease in intracellular calcium when 
activated by BzATP or high concentration of ATP. However, seen as the results involving NFAT 
indicated increased expression of specific molecular bone markers - also presented in this report, 
the same should have been the case for results obtained by RTqPCR in this study. However, this is 
not the case. Instead, the results from RT-qPCR seems incoherent and hard to evaluate. Particularly 
when having a thesis in mind pointing to an increase or decrease in gene expression following a 
gain- or loss-of-function SNP induction respectively.  
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Conclusion and perspective 
We successfully induced three SNPs into the P2X7 receptor gene and subsequently, we transiently 
transfected these into the ROS cell line. When functionally examining the SNPs by means of a 
calcium assay and confirmed the gain- and loss-of-function phenotype for two of them. One turned 
out not to be confirmed in its gain-of-function. For the RT-qPCR, the results did not point in the 
direction of the thesis. However, if successful in generating a stabile transfected cell line preferably 
of human origin, the same assays should produce results comparable to that of other studies. 
Moreover, although intracellular pathways associating the P2X7 receptor to a change in specific 
bone markers has been mentioned in this report, the same connection was not obtained in the 
practical experiments of this study. In perspective, it would have been preferable to also include 
different ranges of BzATP stimulation and time of incubation. This might have changed the 
outcome of the one SNP that was unconfirmed in its gain-of-function phenotype. Furthermore, an 
examination of the pore function in P2X7 receptors could have further characterized the phenotype 
of the SNPs used in this report.  
As a conclusive remark, the cellular effect of P2X7 receptor SNPs and their association in the 
development of osteoporosis in osteoblasts were inconclusive and demand more research to be able 
to confirm the implications.   
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